Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease

Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring Pub Date : 2024-04-01 DOI:10.1002/dad2.12590

Sofia Toniolo, Sijia Zhao, A. Scholcz, B. Amein, A. Ganse-Dumrath, A. Heslegrave, Sian Thompson, Sanjay Manohar, Henrik Zetterberg, Masud Husain

{"title":"Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease","authors":"Sofia Toniolo, Sijia Zhao, A. Scholcz, B. Amein, A. Ganse-Dumrath, A. Heslegrave, Sian Thompson, Sanjay Manohar, Henrik Zetterberg, Masud Husain","doi":"10.1002/dad2.12590","DOIUrl":null,"url":null,"abstract":"Abstract INTRODUCTION A major limitation in Alzheimer's disease (AD) research is the lack of the ability to measure cognitive performance at scale—robustly, remotely, and frequently. Currently, there are no established online digital platforms validated against plasma biomarkers of AD. METHODS We used a novel web‐based platform that assessed different cognitive functions in AD patients (N = 46) and elderly controls (N = 53) who were also evaluated for plasma biomarkers (amyloid beta 42/40 ratio, phosphorylated tau ([p‐tau]181, glial fibrillary acidic protein, neurofilament light chain). Their cognitive performance was compared to a second, larger group of elderly controls (N = 352). RESULTS Patients with AD were significantly impaired across all digital cognitive tests, with performance correlating with plasma biomarker levels, particularly p‐tau181. The combination of p‐tau181 and the single best‐performing digital test achieved high accuracy in group classification. DISCUSSION These findings show how online testing can now be deployed in patients with AD to measure cognitive function effectively and related to blood biomarkers of the disease. Highlights This is the first study comparing online digital testing to plasma biomarkers. Alzheimer's disease patients and two independent cohorts of elderly controls were assessed. Cognitive performance correlated with plasma biomarkers, particularly phosphorylated tau (p‐tau)181. Glial fibrillary acidic protein and neurofilament light chain, and less so the amyloid beta 42/40 ratio, were also associated with performance. The best cognitive metric performed at par to p‐tau181 in group classification.","PeriodicalId":516929,"journal":{"name":"Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/dad2.12590","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Abstract INTRODUCTION A major limitation in Alzheimer's disease (AD) research is the lack of the ability to measure cognitive performance at scale—robustly, remotely, and frequently. Currently, there are no established online digital platforms validated against plasma biomarkers of AD. METHODS We used a novel web‐based platform that assessed different cognitive functions in AD patients (N = 46) and elderly controls (N = 53) who were also evaluated for plasma biomarkers (amyloid beta 42/40 ratio, phosphorylated tau ([p‐tau]181, glial fibrillary acidic protein, neurofilament light chain). Their cognitive performance was compared to a second, larger group of elderly controls (N = 352). RESULTS Patients with AD were significantly impaired across all digital cognitive tests, with performance correlating with plasma biomarker levels, particularly p‐tau181. The combination of p‐tau181 and the single best‐performing digital test achieved high accuracy in group classification. DISCUSSION These findings show how online testing can now be deployed in patients with AD to measure cognitive function effectively and related to blood biomarkers of the disease. Highlights This is the first study comparing online digital testing to plasma biomarkers. Alzheimer's disease patients and two independent cohorts of elderly controls were assessed. Cognitive performance correlated with plasma biomarkers, particularly phosphorylated tau (p‐tau)181. Glial fibrillary acidic protein and neurofilament light chain, and less so the amyloid beta 42/40 ratio, were also associated with performance. The best cognitive metric performed at par to p‐tau181 in group classification.

查看原文本刊更多论文

阿尔茨海默病血浆生物标志物与数字认知测试的关系

摘要引言阿尔茨海默病（AD）研究的一个主要局限是缺乏大规模、远程和频繁测量认知能力的能力。目前，还没有针对阿尔茨海默病血浆生物标志物进行验证的成熟在线数字平台。方法我们使用了一个新颖的网络平台，对注意力缺失症患者（46 人）和老年对照组（53 人）的不同认知功能进行评估，同时还对他们的血浆生物标记物（淀粉样 beta 42/40 比值、磷酸化 tau（[p-tau]181、胶质纤维酸性蛋白、神经丝轻链）进行了评估。他们的认知表现与第二组更多的老年对照组（N = 352）进行了比较。结果在所有数字认知测试中，注意力缺失症患者的认知能力明显受损，其表现与血浆生物标志物水平相关，尤其是p-tau181。结合 p-tau181 和表现最好的单项数字测试，可实现较高的组别分类准确性。讨论这些研究结果表明，现在可以在注意力缺失症患者中使用在线测试来有效测量认知功能，并与该疾病的血液生物标记物相关联。亮点这是第一项将在线数字测试与血浆生物标志物进行比较的研究。对阿尔茨海默病患者和两个独立的老年对照组进行了评估。认知表现与血浆生物标志物相关，尤其是磷酸化 tau（p-tau）181。胶质纤维酸性蛋白和神经丝蛋白轻链也与认知能力有关，而淀粉样β 42/40 比值与认知能力关系不大。最佳认知指标在组别分类中的表现与 p-tau181 相当。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring

自引率

0.00%

发文量